Actively Recruiting
Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
Led by Checkmab S.r.l. · Updated on 2025-02-24
600
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
Sponsors
C
Checkmab S.r.l.
Lead Sponsor
F
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborating Sponsor
AI-Summary
What this Trial Is About
The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.
CONDITIONS
Official Title
Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Blood donors
- Age of 18 years or more
- Able to sign informed consent
You will not qualify if you...
- Age below 18 years
- Positive for HIV, HCV, HBV
- Not suitable for blood donation
- Not able to understand or sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
S.C. Medicina Trasfusionale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy, 20122
Actively Recruiting
Research Team
R
Renata M Grifantini, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here